# Virta Health

> Virta Health is a digital health company on a mission to reverse type 2 diabetes and obesity in 100 million people. Founded in 2014 by Sami Inkinen, Dr. Stephen Phinney, and Dr. Jeff Volek, Virta pairs a nutrition-first, low-carbohydrate clinical protocol with a Continuous Remote Care platform - a mobile app, dedicated physicians and health coaches, and AI-driven personalization - to lower blood sugar, cut medications, and produce durable weight loss without relying on costly drugs or surgery. Sold to employers and health plans on a value-based, outcomes-guaranteed model, Virta has treated over 100,000 members and surpassed $160M in annualized revenue.

- **Founded:** 2014
- **Headquarters:** Denver, Colorado, United States
- **Founders:** Sami Inkinen (Co-Founder & CEO), Stephen Phinney (Co-Founder & Chief Medical Officer), Jeff Volek (Co-Founder & Chief Science Officer)
- **Team size:** ~800-900 employees across five continents
- **Products:** Type 2 Diabetes Reversal, Sustainable Weight Loss, Responsible Prescribing / GLP-1 Management, Continuous Remote Care platform
- **Notable:** Peer-reviewed clinical results: 94% of insulin users reduced or eliminated insulin and 63% of diabetes prescriptions eliminated at one year, Reached a $2.1B valuation with a $133M Series E in 2021, Treated more than 100,000 members for diabetes and obesity

## Products & services

- **Type 2 Diabetes Reversal** — A clinically validated program combining individualized nutrition therapy (low-carbohydrate / nutritional ketosis), continuous physician supervision, and health coaching to lower HbA1c and reduce or eliminate diabetes medications including insulin.
- **Sustainable Weight Loss** — A nutrition-first obesity treatment clinically shown to match or exceed GLP-1 results - about 13% average body weight loss at one year - delivered through coaching, app-based tracking, and medical oversight.
- **Responsible Prescribing / GLP-1 Management** — Medication support that prescribes GLP-1 drugs only when appropriate and helps members taper off, reducing ongoing GLP-1 utilization and payer drug spend.
- **Continuous Remote Care platform** — The core technology: a mobile app integrating biometric feeds (blood glucose, ketones, weight), real-time messaging with a dedicated care team, and AI-driven personalization of dietary and care plans at scale.

## Achievements

- Peer-reviewed clinical results: 94% of insulin users reduced or eliminated insulin and 63% of diabetes prescriptions eliminated at one year
- Reached a $2.1B valuation with a $133M Series E in 2021
- Treated more than 100,000 members for diabetes and obesity
- Crossed $160M in annualized revenue with 80%+ YoY growth (2025)
- Named to the CNBC Disruptor 50 list (2022 and 2025)
- Launched industry-first cost guarantees pledging 0% GLP-1 utilization growth for employers (2025)

## Latest updates

- **2025-09** — Surpassed $160M in annualized revenue, with more than 80% year-over-year growth.
- **2025-06** — Launched industry-first cost guarantees promising 0% GLP-1 utilization trend and guaranteed weight loss for employers and health plans; named again to CNBC Disruptor 50.
- **2025-06** — Published survey showing members who tapered off GLP-1s under medical guidance were 8x more likely to keep losing weight (56%) versus those who quit abruptly (7%).
- **2025-04** — Reported early results showing Responsible Prescribing cut ongoing GLP-1 use by over 50% among current users while sustaining outcomes.
- **2025-01** — Announced record growth at more than $100M in annualized revenue, driven by sustainable weight loss and GLP-1 solutions.

## Links

- Website: https://www.virtahealth.com
- LinkedIn: https://www.linkedin.com/company/virta-health
- Twitter/X: https://twitter.com/virtahealth
- YouTube: https://www.youtube.com/c/VirtaHealth
- Instagram: https://www.instagram.com/virtahealth/
- Facebook: https://www.facebook.com/virtahealth/

---

Profile page: https://yespress.io/virta-health
Published by YesPress — https://yespress.io
Last updated: 2026-06-10